Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 18/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587089 | 1.00 | MAPKAPK2 (0.41) | MAPKAPK2MAPK9CDC7MAP3K14 | |
| SCHEMBL3573060 | 0.93 | MAPKAPK2 (0.40) | MAPKAPK2MAPK9CDC7MAP3K14 | |
| SCHEMBL3573058 | 0.93 | MAPKAPK2 (0.40) | MAPKAPK2MAPK9CDC7MAP3K14 | |
| SCHEMBL3569341 | 0.81 | MAPKAPK2 (0.55) | MAPKAPK2MAPK9CDC7 | |
| SCHEMBL3575771 | 0.77 | DYRK1A (0.53) | MAPKAPK2MAPK9CDC7MAP3K14 | |
| SCHEMBL3577945 | 0.76 | CDC7 (0.66) | MAPKAPK2MAPK9CDC7 | |
| SCHEMBL3574331 | 0.74 | MAPKAPK2 (0.65) | MAPKAPK2MAPK9CDC7 | |
| SCHEMBL3583945 | 0.72 | MAPKAPK2 (0.62) | MAPKAPK2MAPK9CDC7 | |
| SCHEMBL13462373 | 0.72 | MAPKAPK2 (0.34) | MAPKAPK2MAPK9CDC7 | |
| SCHEMBL3569556 | 0.71 | MAPKAPK2 (0.49) | MAPKAPK2MAPK9CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069360-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2064212-A1 | PYRROLO ISOQUINOLINES AS KINASE INHIBITORS | Novartis AG (CH) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008025512-A1 | PYRROLO ISOQUINOLINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069360-A1 | ORGANIC COMPOUNDS | SLCO1B3, CYP3A7, SLCO1B1 | MAPKAPK2 4563/4885MAPK9 2834/4885CDC7 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.